Search

Your search keyword '"Pastorello E"' showing total 36 results
Start Over Author "Pastorello E" Database OAIster
36 results on '"Pastorello E"'

1. Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients

Author

Asero, R, Abbadessa, S, Aruanno, A, Barilaro, G, Barzaghi, C, Bignardi, D, Bilò, M B, Borro, M, Bresciani, M, Busa, M, Buzzulini, F, Cavaliere, C, Cecchi, L, Ciccarelli, A, Cortellini, G, Cucinelli, F, Deleonardi, G, Emiliani, F, Farsi, A, Ferrarini, E, Franchini, M, Ingrassia, A, Lippolis, D, Losappio, L, Marra, A M, Martini, M, Masieri, S, Mauro, M, Mazzolini, M, Muratore, L, Murzilli, F, Nucera, E, Pastorello, E A, Pinter, E, Polillo, B R, Pravettoni, V, Quercia, O, Rizzi, A, Russello, M, Sacerdoti, C, Scala, E, Scala, G, Scarpa, A, Schroeder, J, Uasuf, G G, Villalta, D, Yang, B, Mistrello, G, Amato, S, Lidholm, J, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Asero, R, Abbadessa, S, Aruanno, A, Barilaro, G, Barzaghi, C, Bignardi, D, Bilò, M B, Borro, M, Bresciani, M, Busa, M, Buzzulini, F, Cavaliere, C, Cecchi, L, Ciccarelli, A, Cortellini, G, Cucinelli, F, Deleonardi, G, Emiliani, F, Farsi, A, Ferrarini, E, Franchini, M, Ingrassia, A, Lippolis, D, Losappio, L, Marra, A M, Martini, M, Masieri, S, Mauro, M, Mazzolini, M, Muratore, L, Murzilli, F, Nucera, E, Pastorello, E A, Pinter, E, Polillo, B R, Pravettoni, V, Quercia, O, Rizzi, A, Russello, M, Sacerdoti, C, Scala, E, Scala, G, Scarpa, A, Schroeder, J, Uasuf, G G, Villalta, D, Yang, B, Mistrello, G, Amato, S, Lidholm, J, Nucera, E (ORCID:0000-0002-0565-7680), and Rizzi, A (ORCID:0000-0002-6795-746X)

Abstract

Background: Peach gibberellin-regulated protein (peamaclein) has recently emerged as a relevant food allergen in cypress pollen-hypersensitive patients. Objective: We looked for mono-sensitization to peamaclein among Italian cypress-pollen allergic patients. Material and methods: 835 cypress pollen hypersensitive patients from 28 Italian allergy centers under went thorough interview for food-allergic reactions, and SPT with a commercial peach extracts containing peamaclein. In peach reactors, IgE to rPru p 3 was measured, and those scoring negative were enrolled as potentially mono-sensitized to peamaclein. IgE reactivity to rPru p 7 was evaluated by immunoblot and by an experimental ImmunoCAP with rPru p 7. Results: Peach SPT scored positive in 163 (19.5%) patients but 127 (77,9%) were excluded because Pru p 3 reactors. Twenty-four (14,7%, corresponding to 2.8% of the entire study population) were considered as potentially mono-sensitized to peamaclein. Their distribution did not show any geographic preference. Seventeen/24 (70,8%) had a history of food allergy, in most cases (n=15) to peach. Other offending foods included other Rosaceae, citrus fruits, fig, melon, tree nuts, and kiwi. On peach immunoblot, only 3/18 putative peamaclein allergic subjects reacted to a band at about 7kDa; 4 other patients reacted at about 50-60 kDa. Ten/18 (56%) scored positive for Pru p 7 on ImmunoCAP. Conclusion: Peamaclein allergy and sensitization prevalence seem rare in Italy. Most patients react to peach, albeit other Rosaceae fruits and several citrus fruits may also act as offending foods. Peach and cypress pollen probably share also cross-reacting allergens other than peamaclein.

Published
2020

2. Evaluation of two commercial peach extracts for skin prick testing in the diagnosis of hypersensitivity to lipid transfer protein. A multicenter study

Author

Asero, R, Aruanno, A, Bresciani, Marco Torkel, Brusca, I, Carollo, M, Cecchi, L, Cortellini, G, Deleonardi, G, Farsi, A, Ferrarini, E, Gabrielli, Francesca Augusta, Ingrassia, A, Mauro, M, Murzilli, F, Nucera, Eleonora, Onida, R, Pastorello, E A, Pinter, E, Rizzi, Angela, Russello, M, Sacerdoti, C, Scala, G, Villalta, D, Zampogna, S, Amato, S, Mistrello, G, Scala, E, Bresciani, M, Gabrielli, G, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Asero, R, Aruanno, A, Bresciani, Marco Torkel, Brusca, I, Carollo, M, Cecchi, L, Cortellini, G, Deleonardi, G, Farsi, A, Ferrarini, E, Gabrielli, Francesca Augusta, Ingrassia, A, Mauro, M, Murzilli, F, Nucera, Eleonora, Onida, R, Pastorello, E A, Pinter, E, Rizzi, Angela, Russello, M, Sacerdoti, C, Scala, G, Villalta, D, Zampogna, S, Amato, S, Mistrello, G, Scala, E, Bresciani, M, Gabrielli, G, Nucera, E (ORCID:0000-0002-0565-7680), and Rizzi, A (ORCID:0000-0002-6795-746X)

Abstract

The clinical usefulness of two commercial peach extracts for SPT (by Lofarma SpA and ALK-Abellò, respectively) was compared in a multicenter study carried out in Italy. Peach allergic patients were tested with the two extracts in parallel and underwent the detection of IgE specific for all three peach allergens currently available (Pru p 1, Pru p 3, and Pru p4, respectively). The two extracts were almost identical in terms of sensitivity and specificity, being able to detect virtually all patients sensitized to stable peach allergens (lipid transfer protein [LTP] and, presumably, peamaclein) but scoring negative in patients exclusively sensitive to labile allergens (either PR-10 and/or profilin). Thus, the two extracts represent an excellent tool to carry out a preliminary component-resolved diagnosis of peach allergy at the first patient visit

Published
2020

3. Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients

Author

Schroeder, J, Folci, M, Losappio, L, Chevallard, M, Sinico, R, Mirone, C, De Luca, F, Nichelatti, M, Pastorello, E, Schroeder, Jan Walter, Folci, Marco, Losappio, Laura Michelina, Chevallard, Michel, Sinico, Renato Alberto, Mirone, Corrado, De Luca, Fabrizio, Nichelatti, Michele, Pastorello, Elide Anna, Schroeder, J, Folci, M, Losappio, L, Chevallard, M, Sinico, R, Mirone, C, De Luca, F, Nichelatti, M, Pastorello, E, Schroeder, Jan Walter, Folci, Marco, Losappio, Laura Michelina, Chevallard, Michel, Sinico, Renato Alberto, Mirone, Corrado, De Luca, Fabrizio, Nichelatti, Michele, and Pastorello, Elide Anna

Abstract

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with asthma, anti-neutrophil cytoplasmic antibodies (ANCA) positivity, and tissue eosinophilia. Objective: To describe the presenting clinical features, significant biochemical alterations, and also potential pathogenic factors in adult patients diagnosed in our Center over a period of >20 years. Method: A retrospective study of EGPA patients diagnosed from 1994 to 2019 at ASST Grande Ospedale Metropolitano Niguarda Ca' Granda, Milan (Italy), which was performed according to the 1990 American College of Rheumatology criteria and Chapel Hill Consensus Conference definition. A dataset was compiled, registering demographic and clinical features, biochemical analysis at onset, and also the therapies received 3 months prior to EGPA diagnose. Statistical analyses were subsequently conducted dividing patients in 2 groups based on ANCA positivity and comparing them. Results: Two groups were clearly identified by ANCA serology and specific organ involvement in accordance with literature reports; however, our data underline for the first time the association between anti-leukotriene receptor antagonists (LTRAs) and ANCA positivity. The group of previously treated patients presents an OR of 6.42 to be ANCA positive. This finding could be attributed to an imbalanced stimulation of leukotriene receptors, inducing both mast cells activation and an increased neutrophil extracellular traps release from neutrophils. Conclusion: Despite the limitations of this retrospective study, the association between LTRAs and ANCA antibodies elucidates the mechanism by which innate immunity is directly involved in tolerance breakdown and autoantibodies production. Validation of our results with targeted studies could clarify the differences between ANCA-positive and ANCA-negative patients with important consequences on the use of some drug classes in the treatment of EGPA and asthmatic subjects.

Published
2019

4. House dust mite allergy and shrimp allergy: a complex interaction

Author

Celi, G, Brusca, I, Scala, E, Villalta, D, Pastorello, E, Farioli, L, Cortellini, G, Deleonardi, G, Galati, P, Losappio, L, Manzotti, G, Pirovano, B, Muratore, L, Murzilli, F, Cucinelli, F, Musarra, Teresa, Cilia, M, Nucera, Eleonora, Aruanno, A, Ria, Francesco, Patria, M F, Varin, E, Polillo, B R, Sargentini, V, Quercia, O, Uasuf, C G, Zampogna, S, Carollo, M, Graci, S, Asero, R, Musarra, A, Nucera, E (ORCID:0000-0002-0565-7680), Ria, F (ORCID:0000-0002-8444-0307), Celi, G, Brusca, I, Scala, E, Villalta, D, Pastorello, E, Farioli, L, Cortellini, G, Deleonardi, G, Galati, P, Losappio, L, Manzotti, G, Pirovano, B, Muratore, L, Murzilli, F, Cucinelli, F, Musarra, Teresa, Cilia, M, Nucera, Eleonora, Aruanno, A, Ria, Francesco, Patria, M F, Varin, E, Polillo, B R, Sargentini, V, Quercia, O, Uasuf, C G, Zampogna, S, Carollo, M, Graci, S, Asero, R, Musarra, A, Nucera, E (ORCID:0000-0002-0565-7680), and Ria, F (ORCID:0000-0002-8444-0307)

Abstract

Summary:Background and Objective. Sensitization and allergy to shrimp among Italian house dust mite allergic patients are not well defined and were investigated in a large multicenter study. Methods. Shrimp sensitization and allergy were assessed in 526 house dust mite (HDM)-allergic patients submitted to the detection of IgE to Der p 10 and 100 atopic control not sensitized to HDM. Results. Shrimp allergy occurred in 9% of patients (vs 0% of 100 atopic controls not sensitized to HDM; p minor 0.001). Shrimp-allergic patients were less frequently hypersensitive to airborne allergens other than HDM than crustacean-tolerant subjects (35% vs 58.8%; p minor 0.005). Only 51% of tropomyosin-sensitized patients had shrimp allergy, and these showed significantly higher Der p 10 IgE levels than shrimp-tolerant ones (mean 22.2 KU/l vs 6.2 KU/l; p minor 0.05). Altogether 53% of shrimp-allergic patients did not react against tropomyosin. Conclusions. Shrimp allergy seems to occur uniquely in association with hypersensitivity to HDM allergens and tropomyosin is the main shrimp allergen but not a major one, at least in Italy. Along with tropomyosin-specific IgE levels, monosensitization to HDM seems to represent a risk factor for the development of shrimp allergy among HDM allergic patients.

Published
2019

5. Mast cells and acute coronary syndromes: Relationship between serum tryptase, clinical outcome and severity of coronary artery disease

Author

Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, GIANNATTASIO, CRISTINA, Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, and GIANNATTASIO, CRISTINA

Abstract

Objective: To assess the relationship between serum tryptase and the occurrence of major cardiovascular and cerebrovascular events (MACCE) at 2-year followup in patients admitted with acute coronary syndrome (ACS). To compare serum tryptase to other validated prognostic markers (maximum high-sensitivity troponin (hs-Tn), C reactive protein (CRP) levels at admission, Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score). Methods: We measured serum tryptase at admission in 140 consecutive patients with ACS and in 50 healthy controls. The patients' follow-up was maintained for 2 years after discharge. The predictive accuracy of serum tryptase for 2-year MACCE was assessed and compared with hs-Tn, CRP and SYNTAX score. Results: Serum tryptase levels at admission were significantly higher in patients with ACS compared with the control group (p=0.0351). 2 years after discharge, 28/140 patients (20%) experienced MACCE. Serum tryptase levels, maximum hs-Tn measurements and SYNTAX score were higher in patients who experienced MACCE compared with those without (p<0.0001). Conversely, we found no significant association between MACCE and CRP. The predictive accuracy of serum tryptase for MACCE was set at the cut-off point of 6.7 ng/mL (sensitivity 46%, specificity 84%). Conclusions: In patients with ACS, serum tryptase measured during index admission is significantly correlated to the development of MACCE up to 2 years, demonstrating a possible long-term prognostic role of this biomarker.

Published
2016

6. Mast cells and acute coronary syndromes: Relationship between serum tryptase, clinical outcome and severity of coronary artery disease

Author

Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, GIANNATTASIO, CRISTINA, Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, and GIANNATTASIO, CRISTINA

Abstract

Objective: To assess the relationship between serum tryptase and the occurrence of major cardiovascular and cerebrovascular events (MACCE) at 2-year followup in patients admitted with acute coronary syndrome (ACS). To compare serum tryptase to other validated prognostic markers (maximum high-sensitivity troponin (hs-Tn), C reactive protein (CRP) levels at admission, Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score). Methods: We measured serum tryptase at admission in 140 consecutive patients with ACS and in 50 healthy controls. The patients' follow-up was maintained for 2 years after discharge. The predictive accuracy of serum tryptase for 2-year MACCE was assessed and compared with hs-Tn, CRP and SYNTAX score. Results: Serum tryptase levels at admission were significantly higher in patients with ACS compared with the control group (p=0.0351). 2 years after discharge, 28/140 patients (20%) experienced MACCE. Serum tryptase levels, maximum hs-Tn measurements and SYNTAX score were higher in patients who experienced MACCE compared with those without (p<0.0001). Conversely, we found no significant association between MACCE and CRP. The predictive accuracy of serum tryptase for MACCE was set at the cut-off point of 6.7 ng/mL (sensitivity 46%, specificity 84%). Conclusions: In patients with ACS, serum tryptase measured during index admission is significantly correlated to the development of MACCE up to 2 years, demonstrating a possible long-term prognostic role of this biomarker.

Published
2016

7. Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic review and meta-analysis

Author

Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

8. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews

Author

Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)

Published
2017
Full Text
View/download PDF

9. Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic review and meta-analysis

Author

Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

10. Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic review and meta-analysis

Author

Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

11. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Author

CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

12. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews

Author

Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, Sheikh, A (Aziz), Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, and Sheikh, A (Aziz)

Published
2017

13. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity

Author

Cortellini, G, Romano, Antonino, Santucci, A., Barbaud, A., Bavbek, S., Bignardi, D., Blanca, M., Bonadonna, P., Costantino, M. T., Laguna, J. J., Lombardo, Carla, Losappio, L. M., Makowska, J., Nakonechna, A., Quercia, O., Pastorello, E. A., Patella, V., Terreehorst, I., Testi, S., Cernadas, J. R., Dionicio Elera, J., Lippolis, D., Voltolini, S., Grosseto, D., Romano, Antonino (ORCID:0000-0003-3762-2084), Cortellini, G, Romano, Antonino, Santucci, A., Barbaud, A., Bavbek, S., Bignardi, D., Blanca, M., Bonadonna, P., Costantino, M. T., Laguna, J. J., Lombardo, Carla, Losappio, L. M., Makowska, J., Nakonechna, A., Quercia, O., Pastorello, E. A., Patella, V., Terreehorst, I., Testi, S., Cernadas, J. R., Dionicio Elera, J., Lippolis, D., Voltolini, S., Grosseto, D., and Romano, Antonino (ORCID:0000-0003-3762-2084)

Abstract

Background: Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, this study aimed to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization. Methods: Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel. Results: Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of nonimmediate cutaneous eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 subjects underwent desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, seven at doses up to 500 mg, three at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%. Conclusions: In patients with stable CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization.

Published
2017

14. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

15. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

16. Allergy immunotherapy across the life cycle to promote active and healthy ageing

Author

University of Helsinki, Clinicum, Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., University of Helsinki, Clinicum, Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., and Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

17. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

Author

Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), Bousquet, J. (Jean), Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), and Bousquet, J. (Jean)

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016
Full Text
View/download PDF

18. Allergen immunotherapy for allergic rhinoconjunctivitis: Protocol for a systematic review

Author

Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently scree

Published
2016
Full Text
View/download PDF

19. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

20. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

21. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies

Author

Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., and Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

22. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

23. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

24. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

25. EAACI Molecular Allergology User's Guide

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

26. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies

Author

Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., and Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

27. Allergy immunotherapy across the life cycle to promote active and healthy ageing:from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

28. EAACI molecular allergology user's guide

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H.J., Valenta, R, Hilger, C, Hofmaier, S, Aalberse, R C, Agache, I, Asero, R, Ballmer-Weber, B, Barber, D, Beyer, K, Biedermann, T, Bilò, M B, Blank, S, Bohle, B, Bosshard, P P, Breiteneder, H, Brough, H A, Caraballo, L, Caubet, J C, Crameri, R, Davies, J M, Douladiris, N, Ebisawa, M, EIgenmann, P A, Fernandez-Rivas, M, Ferreira, F, Gadermaier, G, Glatz, M, Hamilton, R G, Hawranek, T, Hellings, P, Hoffmann-Sommergruber, K, Jakob, T, Jappe, U, Jutel, M, Kamath, S D, Knol, E F, Korosec, P, Kuehn, A, Lack, G, Lopata, A L, Mäkelä, M, Morisset, M, Niederberger, V, Nowak-Węgrzyn, A H, Papadopoulos, N G, Pastorello, E A, Pauli, G, Platts-Mills, T, Posa, D, Poulsen, L. K., Raulf, M, Sastre, J, Scala, E, Schmid, J M, Schmid-Grendelmeier, P, van Hage, M, van Ree, R, Vieths, S, Weber, R, Wickman, M, Muraro, A, Ollert, M., Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H.J., Valenta, R, Hilger, C, Hofmaier, S, Aalberse, R C, Agache, I, Asero, R, Ballmer-Weber, B, Barber, D, Beyer, K, Biedermann, T, Bilò, M B, Blank, S, Bohle, B, Bosshard, P P, Breiteneder, H, Brough, H A, Caraballo, L, Caubet, J C, Crameri, R, Davies, J M, Douladiris, N, Ebisawa, M, EIgenmann, P A, Fernandez-Rivas, M, Ferreira, F, Gadermaier, G, Glatz, M, Hamilton, R G, Hawranek, T, Hellings, P, Hoffmann-Sommergruber, K, Jakob, T, Jappe, U, Jutel, M, Kamath, S D, Knol, E F, Korosec, P, Kuehn, A, Lack, G, Lopata, A L, Mäkelä, M, Morisset, M, Niederberger, V, Nowak-Węgrzyn, A H, Papadopoulos, N G, Pastorello, E A, Pauli, G, Platts-Mills, T, Posa, D, Poulsen, L. K., Raulf, M, Sastre, J, Scala, E, Schmid, J M, Schmid-Grendelmeier, P, van Hage, M, van Ree, R, Vieths, S, Weber, R, Wickman, M, Muraro, A, and Ollert, M.

Abstract

The availability of allergen molecules ('components') from several protein families has advanced our understanding of immunoglobulin E (IgE)-mediated responses and enabled 'component-resolved diagnosis' (CRD). The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) provides comprehensive information on important allergens and describes the diagnostic options using CRD. Part A of the EAACI MAUG introduces allergen molecules, families, composition of extracts, databases, and diagnostic IgE, skin, and basophil tests. Singleplex and multiplex IgE assays with components improve both sensitivity for low-abundance allergens and analytical specificity; IgE to individual allergens can yield information on clinical risks and distinguish cross-reactivity from true primary sensitization. Part B discusses the clinical and molecular aspects of IgE-mediated allergies to foods (including nuts, seeds, legumes, fruits, vegetables, cereal grains, milk, egg, meat, fish, and shellfish), inhalants (pollen, mold spores, mites, and animal dander), and Hymenoptera venom. Diagnostic algorithms and short case histories provide useful information for the clinical workup of allergic individuals targeted for CRD. Part C covers protein families containing ubiquitous, highly cross-reactive panallergens from plant (lipid transfer proteins, polcalcins, PR-10, profilins) and animal sources (lipocalins, parvalbumins, serum albumins, tropomyosins) and explains their diagnostic and clinical utility. Part D lists 100 important allergen molecules. In conclusion, IgE-mediated reactions and allergic diseases, including allergic rhinoconjunctivitis, asthma, food reactions, and insect sting reactions, are discussed from a novel molecular perspective. The EAACI MAUG documents the rapid progression of molecular allergology from basic research to its integration into clinical practice, a quantum leap in the management of allergic patients.

Published
2016

29. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies

Author

Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilo, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, de Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, A T, Gerth van Wijk, Roy, Gomez, R M, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, del Rio, PR, Rueff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, M H, Sheikh, A (Aziz), Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, van Ree, R, Ventura, M T, Vidal, C, Varga, EM, Worm, M, Zuberbier, T, Bousquet, J, Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilo, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, de Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, A T, Gerth van Wijk, Roy, Gomez, R M, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, del Rio, PR, Rueff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, M H, Sheikh, A (Aziz), Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, van Ree, R, Ventura, M T, Vidal, C, Varga, EM, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

30. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review

Author

Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, Sheikh, A (Aziz), Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, and Sheikh, A (Aziz)

Published
2016

31. Allergy immunotherapy across the life cycle to promote active and healthy ageing:from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

32. Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy

Author

Ricci, G, Scionti, I, Sera, F, Govi, M, D'Amico, R, Frambolli, I, Mele, F, Filosto, M, Vercelli, L, Ruggiero, L, Berardinelli, A, Angelini, C, Antonini, G, Bucci, E, Cao, M, Daolio, J, Di Muzio, A, Di Leo, R, Galluzzi, G, Iannaccone, E, Maggi, L, Maruotti, V, Moggio, M, Mongini, T, Morandi, L, Nikolic, A, Pastorello, E, Ricci, Enzo, Rodolico, C, Santoro, L, Servida, M, Siciliano, G, Tomelleri, G, Tupler, R., Ricci, Enzo (ORCID:0000-0003-3092-3597), Ricci, G, Scionti, I, Sera, F, Govi, M, D'Amico, R, Frambolli, I, Mele, F, Filosto, M, Vercelli, L, Ruggiero, L, Berardinelli, A, Angelini, C, Antonini, G, Bucci, E, Cao, M, Daolio, J, Di Muzio, A, Di Leo, R, Galluzzi, G, Iannaccone, E, Maggi, L, Maruotti, V, Moggio, M, Mongini, T, Morandi, L, Nikolic, A, Pastorello, E, Ricci, Enzo, Rodolico, C, Santoro, L, Servida, M, Siciliano, G, Tomelleri, G, Tupler, R., and Ricci, Enzo (ORCID:0000-0003-3092-3597)

Abstract

Facioscapulohumeral muscular dystrophy has been genetically linked to reduced numbers (≤ 8) of D4Z4 repeats at 4q35 combined with 4A(159/161/168) DUX4 polyadenylation signal haplotype. However, we have recently reported that 1.3% of healthy individuals carry this molecular signature and 19% of subjects affected by facioscapulohumeral muscular dystrophy do not carry alleles with eight or fewer D4Z4 repeats. Therefore, prognosis for subjects carrying or at risk of carrying D4Z4 reduced alleles has become more complicated. To test for additional prognostic factors, we measured the degree of motor impairment in a large group of patients affected by facioscapulohumeral muscular dystrophy and their relatives who are carrying D4Z4 reduced alleles. The clinical expression of motor impairment was assessed in 530 subjects, 163 probands and 367 relatives, from 176 unrelated families according to a standardized clinical score. The associations between clinical severity and size of D4Z4 allele, degree of kinship, gender, age and 4q haplotype were evaluated. Overall, 32.2% of relatives did not display any muscle functional impairment. This phenotype was influenced by the degree of relation with proband, because 47.1% of second- through fifth-degree relatives were unaffected, whereas only 27.5% of first-degree family members did not show motor impairment. The estimated risk of developing motor impairment by age 50 for relatives carrying a D4Z4 reduced allele with 1-3 repeats or 4-8 repeats was 88.7% and 55%, respectively. Male relatives had a mean score significantly higher than females (5.4 versus 4.0, P = 0.003). No 4q haplotype was exclusively associated with the presence of disease. In 13% of families in which D4Z4 alleles with 4-8 repeats segregate, the diagnosis of facioscapulohumeral muscular dystrophy was reported only in one generation. In conclusion, this large-scale analysis provides further information that should be taken into account when counselling families in whic

Published
2013

33. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis

Author

Cristallo, A, Schroeder, J, Citterio, A, Santori, G, Ferrioli, G, Rossi, U, Bertani, G, Cassano, S, Gottardi, P, Ceschini, N, Barocci, F, Ribizzi, G, Cutrupi, V, Cairoli, R, Rapisarda, V, Pastorello, E, Barocci, S, Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, Barocci S, Cristallo, A, Schroeder, J, Citterio, A, Santori, G, Ferrioli, G, Rossi, U, Bertani, G, Cassano, S, Gottardi, P, Ceschini, N, Barocci, F, Ribizzi, G, Cutrupi, V, Cairoli, R, Rapisarda, V, Pastorello, E, Barocci, S, Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, and Barocci S

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are represented by rare but life-threatening cutaneous adverse reactions to different drugs. Previous studies have found that in a Han Chinese population from Taiwan and other Asian Countries, a strong genetic association between HLA-class I alleles (B*15:02, B*58:01) and SJS and TEN was induced by carbamazepine and allopurinol, respectively. To identify genetic markers that covered the MHC region, we carried out a case-control association enrolling 20 Caucasian patients with SJS/TEN. Our patient series included 10 cases related to paracetamol, 7 to allopurinol and 3 to different drugs (plaquenil, itraconazol, nabumetone). Healthy controls were represented by 115 Caucasian bone marrow or stem cell donors. The HLA-A*, B*, C*, DRB1*, DQB1*, DQA1* and DPB1* genotyping were determined. The frequencies of HLA-A*33:03 as well as C*03:02 and C*08:01 were significantly higher in SJS/TEN patient subgroup showing allopurinol drug-induced severe cutaneous adverse reactions (SCAR) as compared to controls (28.6% vs 0%, P=0.00002, Pc=0.0011; 28.6% vs 0%, P=0.00002, Pc=0.001; 28.6% vs 0%, P=0.00002, Pc=0.001, respectively). In the same subgroup the frequencies of B*58:01, DRB1*15:02 and DRB1*13:02 alleles, although considerably higher than in control group (42.8% vs 5.2%, P=0.003; 28.6% vs 1.7%, P=0.005; 28.6% vs 3.5%, P=0.037, respectively), appeared no more statistically different after P correction (Pc=0.248; Pc=0.29; Pc=1.00, respectively). In addition, in 10 of the 20 SJS/TEN patient subgroup with paracetamol-induced SCAR no statistically significant association with HLA alleles could be found. However, in the same SJS/TEN patient subgroup showing allopurinol drug-induced SCAR, haplotype analysis indicated that B*58:01, DRB1*13:02 and DRB1*15:02 alleles, that in a single allele analysis lost statistical significance after P correction, may still confer susceptibility, because the B*58:01-DRB1*13:02 and DRB1*1

Published
2011

34. Searching for allergens in maize kernels via proteomic tools

Author

Fasoli, Elisa, Pastorello, E. A., Farioli, L, Scibilia, J, Aldini, G, Carini, M, Marocco, Adriano, Boschetti, E, Righetti, Pier Giorgio, Marocco, Adriano (ORCID:0000-0001-5378-5591), Fasoli, Elisa, Pastorello, E. A., Farioli, L, Scibilia, J, Aldini, G, Carini, M, Marocco, Adriano, Boschetti, E, Righetti, Pier Giorgio, and Marocco, Adriano (ORCID:0000-0001-5378-5591)

Abstract

Up to the present, only one major allergen had been univocally identified by chemical analysis (N-terminal sequencing) in the salt-extractable (cytoplasmic) protein fraction of maize kernels (Zea mays): the lipid transfer protein (Pastorello et al., Allergy Clin. Immunol. 2000;106:744–751). In the present study, two-dimensional maps of kernel flour have been set up, the proteins transferred to nitrocellulose membranes and confronted with sera of various patients allergic to maize proteins. Via spot excision and Orbitrap mass analysis, the following new allergens have been identified: vicilin, globulin-2, 50 kDa gamma-zein, endochitinase, thioredoxin and trypsin inhibitor. Vicilin was found to be composed of a string of six spots, all of them allergenic; also globulin-2 was composed of a string of five spots, exhibiting equivalent allergenicity. The 50 kDa gamma-zein, found here in the maize flour soluble fraction, is identical to the 50 kDa allergen reported by Pasini et al. (Allergy 2002; 57:98–106), but present in the insoluble fraction and solubilized via -S-S- reducing agents. However, the form here described might be a truncated species, since it exhibits an apparent Mr, in SDS-PAGE, of ca. 35 kDa. The homology of three of them (vicilin, globulin-2 and thioredoxin) with other vegetable systems has been investigated via BLAST analysis, the ones with highest homology belonging to rice, wheat and barley. The present data add a non-negligible amount of previously unreported allergens to the scanty panorama of maize proteins.

Published
2009

35. Hazelnut allergy:a double-blind, placebo-controlled food challenge multicenter study

Author

Ortolani, C, Ballmer-Weber, B K, Hansen, K S, Ispano, M, Wüthrich, B, Bindslev-Jensen, C, Ansaloni, R, Vannucci, L, Pravettoni, V, Scibilia, J, Poulsen, L K, Pastorello, E A, Ortolani, C, Ballmer-Weber, B K, Hansen, K S, Ispano, M, Wüthrich, B, Bindslev-Jensen, C, Ansaloni, R, Vannucci, L, Pravettoni, V, Scibilia, J, Poulsen, L K, and Pastorello, E A

Abstract

BACKGROUND: Tree nuts are a common cause of food allergy in Europe. However, few studies deal with real food allergy to hazelnuts in subjects believed to be allergic to this food.OBJECTIVE: We sought to select subjects with a history of allergic reactions on ingestion of hazelnut and determine how many of these have true allergy by means of the double-blind, placebo-controlled food challenge (DBPCFC).METHODS: Eighty-six subjects with a history of symptoms after hazelnut ingestion were recruited from 3 allergy centers (Milan, Zurich, and Copenhagen). All subjects underwent skin prick tests (SPTs) with aeroallergens and hazelnut, as well as having their specific hazelnut IgE levels determined. Diagnosis of clinical relevant food allergy was made on the basis of the DBPCFC.RESULTS: Sixty-seven (77.9%) of 86 subjects had a positive DBPCFC result; 8 were placebo responders, and 11 were nonresponders. Of the 11 nonresponders, 4 had positive open-challenge test results. Of the DBPCFC-positive subjects, 87% also had positive skin test responses to birch pollen extract. Specific IgE determination for hazelnut (positive CAP response >/=0.7 kU/L [ie, class 2]) showed a sensitivity of 0.75, a positive predictive value (PPV) of 0.92, a specificity of 0.16, and a negative predictive value (NPV) of 0.05. Skin tests with commercial hazelnut extract produced a sensitivity of 0.89, a PPV of 0.92, a specificity of 0.05, and an NPV of 0.05. Skin tests with natural food produced a sensitivity of 0.88, a PPV of 0.94, a specificity of 0.27, and an NPV of 0.15.CONCLUSION: This study shows that hazelnut is an allergenic source that can cause real food allergy, as confirmed by DBPCFC. Skin and IgE tests demonstrated reasonable sensitivity and PPV but a very low specificity and NPV, thus implying that these should not be used to validate the diagnosis of food allergy to hazelnut.

Published
2000

36. Hazelnut allergy:a double-blind, placebo-controlled food challenge multicenter study

Author

Ortolani, C, Ballmer-Weber, B K, Hansen, K S, Ispano, M, Wüthrich, B, Bindslev-Jensen, C, Ansaloni, R, Vannucci, L, Pravettoni, V, Scibilia, J, Poulsen, L K, Pastorello, E A, Ortolani, C, Ballmer-Weber, B K, Hansen, K S, Ispano, M, Wüthrich, B, Bindslev-Jensen, C, Ansaloni, R, Vannucci, L, Pravettoni, V, Scibilia, J, Poulsen, L K, and Pastorello, E A

Abstract

BACKGROUND: Tree nuts are a common cause of food allergy in Europe. However, few studies deal with real food allergy to hazelnuts in subjects believed to be allergic to this food.OBJECTIVE: We sought to select subjects with a history of allergic reactions on ingestion of hazelnut and determine how many of these have true allergy by means of the double-blind, placebo-controlled food challenge (DBPCFC).METHODS: Eighty-six subjects with a history of symptoms after hazelnut ingestion were recruited from 3 allergy centers (Milan, Zurich, and Copenhagen). All subjects underwent skin prick tests (SPTs) with aeroallergens and hazelnut, as well as having their specific hazelnut IgE levels determined. Diagnosis of clinical relevant food allergy was made on the basis of the DBPCFC.RESULTS: Sixty-seven (77.9%) of 86 subjects had a positive DBPCFC result; 8 were placebo responders, and 11 were nonresponders. Of the 11 nonresponders, 4 had positive open-challenge test results. Of the DBPCFC-positive subjects, 87% also had positive skin test responses to birch pollen extract. Specific IgE determination for hazelnut (positive CAP response >/=0.7 kU/L [ie, class 2]) showed a sensitivity of 0.75, a positive predictive value (PPV) of 0.92, a specificity of 0.16, and a negative predictive value (NPV) of 0.05. Skin tests with commercial hazelnut extract produced a sensitivity of 0.89, a PPV of 0.92, a specificity of 0.05, and an NPV of 0.05. Skin tests with natural food produced a sensitivity of 0.88, a PPV of 0.94, a specificity of 0.27, and an NPV of 0.15.CONCLUSION: This study shows that hazelnut is an allergenic source that can cause real food allergy, as confirmed by DBPCFC. Skin and IgE tests demonstrated reasonable sensitivity and PPV but a very low specificity and NPV, thus implying that these should not be used to validate the diagnosis of food allergy to hazelnut.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results